HIF-PHI versus EPO with iron in chronic renal failure anaemia [HIF-PHI versus EPO con hierro en anemia de insuficiencia renal crónica]
DOI:
https://doi.org/10.62574/fgrek111Keywords:
anaemia, chronic renal failure, erythropoietinAbstract
Objective: Compare the efficacy and safety of HIF-PHI versus erythropoietin with iron in the treatment of anaemia in patients with chronic renal failure. Method: Systematic review of 16 studies. Results and Conclusion: Although both approaches show similar effectiveness in raising haemoglobin levels, HIF-PHI offer particular benefits by generating a more natural and stable erythropoietic response, improving the utilisation of iron in the body through the regulation of hepcidin, and promoting treatment compliance through their oral administration. However, questions remain about their cardiovascular safety in the medium and long term, particularly regarding the risk of thromboembolic events and the possible stimulation of abnormal cell growth.
Downloads
References
Quiroga B, Abad Esteban S. Anemia en la Enfermedad Renal Crónica. Nefrología. 2024;7(3):1–5.
Mendieta-Barreto EJ, Yoza-Peña JA, Fuentes-Sánchez ET. Prevalencia y diagnóstico de anemia en pacientes con enfermedad renal en Latinoamérica. MQRInvestigar. 2023;7(3):587–605.
Pertuz-Pinzón A, Ismael-Garcia CI, Muñoz-Gómez C, Rico-Fontalvo J, Daza-Arnedo R, Pájaro-Galvis N, et al. Anemia en Enfermedad Renal Crónica. Arch Med. 2021;17(2):1–8. doi: 10.3823/1462.
Heras Benito M. Resistencia a la eritropoyetina en anemia renal: el papel de los estabilizadores del factor inducible por hipoxia. Rev Colomb Nefrol. 2024;11(3):e821.
Haase VH. Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease. Kidney Int Suppl (2011) [Internet]. 2021;11(1):8–25. Disponible en: http://dx.doi.org/10.1016/j.kisu.2020.12.002
de Sales JI, Carreiro CF, Dias YA. Tratamento da anemia na doença renal crônica – revisão descritiva. Rev Foco. 2024;17(7):e5579.
Zuk A, Si Z, Loi S, Bommegowda S, Hoivik D, Danthi S, et al. Preclinical characterization of vadadustat (AKB-6548), an oral small molecule hypoxia-inducible factor prolyl-4-hydroxylase inhibitor, for the potential treatment of renal anemia. J Pharmacol Exp Ther [Internet]. 2022;383(1):11–24. Disponible en: http://dx.doi.org/10.1124/jpet.122.001126
Wish JB. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for the treatment of anemia in CKD: Additional pieces of the jigsaw puzzle. Kidney Int Rep [Internet]. 2021;6(7):1751–4. Disponible en: http://dx.doi.org/10.1016/j.ekir.2021.05.017
Sugahara M, Tanaka T, Nangaku M. Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors. Pharmacol Ther [Internet]. 2022;239(108272):108272. Disponible en: http://dx.doi.org/10.1016/j.pharmthera.2022.108272
Haase VH. Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of anemia of chronic kidney disease. Kidney Int Suppl (2011) [Internet]. 2021;11(1):8–25. Disponible en: http://dx.doi.org/10.1016/j.kisu.2020.12.002
Locatelli F, Minutolo R, De Nicola L, Del Vecchio L. Evolving strategies in the treatment of anaemia in chronic kidney disease: The HIF-prolyl hydroxylase inhibitors. Drugs. 2022;82:1565–89. Disponible en: https://doi.org/10.1007/s40265-022-01783-3
Portolés J, Martín L, Broseta JJ, Cases A. Anemia en la enfermedad renal crónica: desde la fisiopatología y los tratamientos actuales hasta los agentes futuros. Front Med. 2021;8:642296. Disponible en: https://doi.org/10.3389/fmed.2021.642296
Yang J, Xing J, Zhu X, Xie X, Wang L, Zhang X. Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors vs. erythropoiesis-stimulating agents on iron metabolism in non-dialysis-dependent anemic patients with CKD: A network meta-analysis. Front Endocrinol. 2023;14. Disponible en: https://www.frontiersin.org/articles/10.3389/fendo.2023.1131516/full
Grzeszczak W, Szczyra D, Śnit M. Whether Prolyl Hydroxylase Blocker—Roxadustat—In the Treatment of Anemia in Patients with Chronic Kidney Disease Is the Future? Int J Environ Res Public Health. 2021;18(4):1612. Disponible en: https://www.mdpi.com/16604601/18/4/1612
Quiroga B, Abad Esteban S. Anemia en la Enfermedad Renal Crónica. En: Lorenzo V, López-Gómez JM, editores. Navegador temático del conocimiento nefrológico. Sociedad Española de Nefrología; 2024.
Valencia-Herrera AR, Sailema-López LK, Garcell-Duran K. Enfoque diagnóstico y terapéutico de la anemia causada por la insuficiencia renal crónica. Rev Inf Científica [Internet]. 2023;102. Disponible en: http://scielo.sld.cu/scielo.php?pid=S1028-99332023000100063&script=sci_abstract&tlng=pt
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Diana Lorena Jordán-Fiallos , Daniela Rafaela Palacios-Córdova, Mey Anais Vuele-Cuenca, Dariela Scarleth Seme-Albán (Autor/a)
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
CC BY-NC-SA : Esta licencia permite a los reutilizadores distribuir, remezclar, adaptar y construir sobre el material en cualquier medio o formato solo con fines no comerciales, y solo siempre y cuando se dé la atribución al creador. Si remezcla, adapta o construye sobre el material, debe licenciar el material modificado bajo términos idénticos.
